Cargando…
Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
Interpretation of clinical trials to alter the decline in β-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe the natural history of β-cell function from shortly...
Autores principales: | Greenbaum, Carla J., Beam, Craig A., Boulware, David, Gitelman, Stephen E., Gottlieb, Peter A., Herold, Kevan C., Lachin, John M., McGee, Paula, Palmer, Jerry P., Pescovitz, Mark D., Krause-Steinrauf, Heidi, Skyler, Jay S., Sosenko, Jay M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402330/ https://www.ncbi.nlm.nih.gov/pubmed/22688329 http://dx.doi.org/10.2337/db11-1538 |
Ejemplares similares
-
Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011) -
Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011) -
Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018) -
Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
por: Lachin, John M., et al.
Publicado: (2011) -
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)